About Gamida Cell
Gamida Cell is a company based in Jerusalem (Israel) founded in 1998. Gamida Cell has raised $139.12 million across 12 funding rounds from investors including Amgen, Novartis and Teva Pharmaceuticals. Gamida Cell offers products and services including NAM-based Cell Therapies. Gamida Cell operates in a competitive market with competitors including Jazz Pharmaceuticals, Moderna, BridgeBio, C4 Therapeutics and Erasca, among others.
- Headquarter Jerusalem, Israel
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Gamida Cell Ltd.
-
Annual Revenue
$1.78 M (USD)0as on Dec 31, 2023
-
Net Profit
$63 M (USD)-21as on Dec 31, 2023
-
EBITDA
$73.04 M (USD)-3as on Dec 31, 2023
-
Total Equity Funding
$139.12 M (USD)
in 12 rounds
-
Latest Funding Round
$3.5 M (USD), Grant
Jul 20, 2017
-
Investors
Amgen
& 13 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Gamida Cell
Gamida Cell offers a comprehensive portfolio of products and services, including NAM-based Cell Therapies.
Enhances cells for potentially curative treatments of hematologic malignancies
People of Gamida Cell
Unlock access to complete
Unlock access to complete
Funding Insights of Gamida Cell
Gamida Cell has successfully raised a total of $139.12M across 12 strategic funding rounds. The most recent funding activity was a Grant round of $3.5 million completed in July 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Gamida Cell
Gamida Cell has secured backing from 14 investors, including institutional and venture fund investors. Prominent investors backing the company include Amgen, Novartis and Teva Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investments in Israel are managed by Shavit Capital.
|
Locked | Locked | Locked | |
|
Life Sciences focused VC firm investing in Israel and the US
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Gamida Cell
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Gamida Cell
Investment portfolio details for Gamida Cell
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Gamida Cell
Detailed financials for Gamida Cell
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Gamida Cell Comparisons
Peer comparison for Gamida Cell
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Gamida Cell
Gamida Cell operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Moderna, BridgeBio, C4 Therapeutics and Erasca, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
Detailed competitors of Gamida Cell
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Gamida Cell
Complete news archive for Gamida Cell
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Gamida Cell
Gamida Cell was founded in 1998 and raised its 1st funding round 2 years after it was founded.
Gamida Cell is headquartered in Jerusalem, Israel. It is registered at Jerusalem, Jerusalem District, Israel.
Joseph Wiley is the current CEO of Gamida Cell.
Gamida Cell is a funded company, having raised a total of $139.12M across 12 funding rounds to date.
Annual revenue of Gamida Cell is $1.78M as on Dec 31, 2023.
The company was founded in 1998 in Jerusalem, Israel, and operates in the biotechnology sector. Cell therapies are developed using a proprietary NAM platform for allogeneic sources, including umbilical cord blood-derived cells and NK cells, targeted at solid tumors and hematological malignancies. The lead product, omidubicel, is focused on treating hematological malignancies, with operations centered on advancing these therapies for serious diseases.
Gamida Cell's top competitors include Moderna, Jazz Pharmaceuticals and Spark Therapeutics.
Gamida Cell offers NAM-based Cell Therapies.
Gamida Cell has 14 investors. Key investors include Amgen, Novartis, Teva Pharmaceuticals, Israel Innovation Authority, and Clal Biotechnology Industries.